A New Generation of Bioavailability
- with data to back it up.

At Percise™, we believe that scientific data should always be the north star of our products. 

Learn more about the Dent Institute, who heads our research, and see our extensive data presented in many acclaimed medical events.

research

The DENT Institute is a pioneering institution in medical cannabis research, dedicated to exploring the therapeutic potential of cannabinoid-based treatments for a wide range of neurological conditions. Under the esteemed leadership of Dr. Laszlo Mechtler, an internationally recognized authority in Neurology, Neuroimaging, Neuro-Oncology, Headache Medicine, and Cannabinoid Medicine, the center has established itself as a leader in cannabinoid-based clinical research.

Dr. Mechtler’s groundbreaking work has played a critical role in advancing the use of cannabis for neurological disorders and medicine at large.

Since the launch of New York State’s medical cannabis program in 2016, the DENT Cannabis Research Center has expanded into one of the largest physician-directed cannabis clinics in the United States, serving more than 15,000 patients with cannabinoid based therapies. This vast clinical base enables our team to conduct detailed research on conditions such as migraine, neuropathy, Parkinson’s disease, glioblastoma, multiple sclerosis, and others. Our center has been at the forefront of publishing some of the first major retrospective research trials on medical marijuana in headache medicine and other neurological disorders, contributing to numerous peer-reviewed articles and book chapters.  In addition to our retrospective research, we have also undertaken prospective clinical trials, which provide a forward-looking perspective and allow us to collect real-time data on the effects of medical cannabis. These studies offer critical insights into the efficacy and safety of cannabis treatments across various neurological conditions. By combining both retrospective and prospective research, we ensure that our findings not only draw from historical clinical outcomes but also capture the most up-to-date trends and patient responses in cannabinoid medicine. See data below.

Our mission is to advance patient care through research that legitimizes cannabis as a viable medical treatment option. Our studies have shown that cannabis therapies, when administered under proper medical guidance, can be highly effective, enabling many patients to reduce or eliminate the use of conventional pharmaceuticals.

main findings

Cannabis and Migraine

Patients Utilizing Medical Cannabis For Migraine Have Reported Improvement In Migraine Profile And Common Comorbidities. Reduction In Prescription Medication Is Also Common, Especially Opioids.​

Cannabis in the Treatment of Motor Neuron Disease

The findings suggest that medical cannabis may slow motor neuron diseases progression as evidenced by the slower rate of decline in the ALSFRS- R scores.​

Cannabis and Migraine: It’s Complicated

Laszlo L. Mechtler 1 & Fran M. Gengo 2 & Vincent H. Bargnes 1 from the 1 Dent Neurologic Institute, 3980 Sheridan Drive, Suite 600, Amherst, NY 14226, USA and the 2 Dent Neurologic Institute, 3980 Sheridan Drive, Suite 300, Amherst, NY 14226, USA

Cannabis and crash risk among older drivers

Mark B. Johnson a,*, Laszlo Mechtler b, Bina Ali a, David Swedler a, Tara Kelley-Baker c from a Pacific Institute for Research and Evaluation (PIRE), 11720 Beltsville Drive, Suite 900, Calverton, MD 20705, USA and b Dent Neurologic Institute, 3980 Sheridan Drive, Amherst, NY 14226, USA and c AAA Foundation for Traffic Safety, 607 14th Street, NW, Suite 201, Washington, DC 20005-2000, USA

Medical Cannabis treatment in Patients with Trigeminal Neuralgia

Laszlo Mechtler MD, FAAN, FEAN, FASN 1, Paul Hart MA 1, Vincent Bargnes BS 1, from the 1 DENT Neurologic Institute Buffalo, NY, USA

Medical Cannabis in the Treatment of Parkinson’s Disease

Bennett Myers MD; Tanya Geist R-PAC; Traci Aladeen PharmD; Erica Westphal BA/BS; Paul Hart MA; Kory Zelen BS; Alexandra Begley BS; BS; Michelle Rainka PharmD; Stefania Florea BS; Laszlo Mechtler MD FAAN FASN FEAN

Multiple Sclerosis and Use of Medical Cannabis: A Retrospective Review Evaluating Symptom Outcomes

Katelyn McCormack FNP-C, ANP-C; Emily Lewandowski PharmD ; Michelle Rainka, PharmD; Traci Aladeen, PharmD; Erica Westphal BA/BS; Amir C. Mazhari MD; Laszlo Mechtler MD, FAAN, FASN,FEAN

Safety and Efficacy of Medical Cannabis in Elderly Patients

Vincent Bargnes, BS 1,2, Paul Hart, MA 1, Shelia Gupta 1, Nicolas P. Saikali, MD, FAHS 1, Laszlo Mechtler MD, FAAN, FEAN, FASN 1 from the 1 DENT Neurologic Institute Buffalo, NY, USA and the 2 Jacobs School of Medicine and Biomedical Sciences Buffalo, NY, USA

Shop Now

Our products are specifically designed to enhance absorption and effectiveness in your body.

products
Welcome to Percise

You need to be 21 to legally purchase these products. Come back when you’re of age, and we’ll welcome you with a range of CBD to explore.

Welcome to Percise

Please verify that you are at least 21 years old to proceed.

By clicking “yes” and entering this site, I certify that I am of legal age and accept Percise’s Terms & Conditions and Privacy Policy.